头孢地尔与亚胺培南-西司他丁治疗复杂性尿路感染:2期随机双盲非劣效试验
这项2期多中心双盲非劣效试验在15国67家医院纳入452例复杂性尿路感染患者,随机2:1接受头孢地尔2g或亚胺培南-西司他丁1g每日三次静滴7-14天。头孢地尔耐受良好。
要点
- 头孢地尔2g每日三次静滴7-14天治疗复杂性尿路感染非劣效于亚胺培南-西司他丁1g每日三次。
- 头孢地尔组不良事件41%,亚胺培南-西司他丁组51%,胃肠道反应最常见。
核心结论
- 头孢地尔2g每日三次静滴治疗复杂性尿路感染非劣效于亚胺培南-西司他丁1g每日三次。
- 头孢地尔耐受良好,为多重耐药革兰阴性菌感染提供潜在治疗选择。
研究设计与样本
- 2期多中心双盲平行组非劣效试验,在15国67家医院进行。
- 纳入≥18岁住院的复杂性尿路感染伴或不伴肾盂肾炎或急性非复杂性肾盂肾炎患者,随机2:1分组。
- 头孢地尔2g或亚胺培南-西司他丁1g(各1g)每日三次静滴,疗程7-14天。
- 主要终点为治愈访视(停药后7天)临床与微生物学复合终点,非劣效界值15%和20%。
- 主要疗效分析基于改良意向治疗人群,即至少接受一剂研究药物且基线尿培养有合格革兰阴性尿路病原体(≥1×10^5 CFU/mL)者。
主要发现
- 2015年2月5日至2016年8月16日共随机452例,头孢地尔组303例、亚胺培南-西司他丁组149例;448例接受治疗。
- 371例纳入主要疗效分析:头孢地尔组252例、亚胺培南-西司他丁组119例。
- 治愈访视时主要终点达标:头孢地尔组183/252(73%),亚胺培南-西司他丁组65/119(55%)。
- 不良事件发生率头孢地尔组122/300(41%),亚胺培南-西司他丁组76/148(51%);胃肠道疾病最常见(头孢地尔组35/300[12%],亚胺培南-西司他丁组27/148[18%])。
关键数值与推荐
- 非劣效界值:15%和20%。
- 不良事件:头孢地尔41% vs 亚胺培南-西司他丁51%;胃肠道反应12% vs 18%。
临床怎么用
- 对于复杂性尿路感染(含急性非复杂性肾盂肾炎)且存在多重耐药革兰阴性菌风险的患者,可考虑头孢地尔2g每日三次静滴7-14天。
- 该研究排除了碳青霉烯耐药病原体感染、真菌性尿路感染及基线尿培养超过两种尿路病原体的患者,临床应结合本地耐药流行病学选用。
- 头孢地尔组不良事件发生率较低,但需关注胃肠道反应。
局限性
- 为2期试验,样本量有限,主要疗效分析仅371例。
- 排除了碳青霉烯耐药病原体感染患者,结论不能直接外推至碳青霉烯耐药菌感染。
- 研究由药企资助,随访至治愈访视(停药后7天),长期疗效与耐药发展未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbapenem-resistant Gram-negative bacteria represent the highest priority for addressing global antibiotic resistance. Cefiderocol (S-649266), a new siderophore cephalosporin, has broad activity against Enterobacteriaceae and non-fermenting bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, including carbapenem-resistant strains. We assessed the efficacy and safety of cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infection in patients at risk of multidrug-resistant Gram-negative infections. METHODS: We did a phase 2, multicentre, double-blind, parallel-group non-inferiority trial at 67 hospitals in 15 countries. Adults (≥18 years) admitted to hospital with a clinical diagnosis of complicated urinary tract infection with or without pyelonephritis or those with acute uncomplicated pyelonephritis were randomly assigned (2:1) by an interactive web or voice response system to receive 1 h intravenous infusions of cefiderocol (2 g) or imipenem-cilastatin (1 g each) three times daily, every 8 h for 7-14 days. Patients were excluded if they had a baseline urine culture with more than two uropathogens, a fungal urinary tract infection, or pathogens known to be carbapenem resistant. The primary endpoint was the composite of clinical and microbiological outcomes at test of cure (ie, 7 days after treatment cessation), which was used to establish non-inferiority (15% and 20% margins) of cefiderocol versus imipenem-cilastatin. The primary efficacy analysis was done on a modified intention-to-treat population, which included all randomly assigned individuals who received at least one dose of study drug and had a qualifying Gram-negative uropathogen (≥1 × 105 colony-forming units [CFU]/mL). Safety was assessed in all randomly assigned individuals who received at least one dose of study drug, according to the treatment they received. This study is registered with ClinicalTrials.gov, number NCT02321800. FINDINGS: Between Feb 5, 2015, and Aug 16, 2016, 452 patients were randomly assigned to cefiderocol (n=303) or imipenem-cilastatin (n=149), of whom 448 patients (n=300 in the cefiderocol group; n=148 in the imipenem-cilastatin group) received treatment. 371 patients (n=252 patients in the cefiderocol group; n=119 patients in the imipenem-cilastatin group) had qualifying Gram-negative uropathogen (≥1 × 105 CFU/mL) and were included in the primary efficacy analysis. At test of cure, the primary efficacy endpoint was achieved by 183 (73%) of 252 patients in the cefiderocol group and 65 (55%) of 119 patients in the imipenem-cilastatin group, with an adjusted treatment difference of 18·58% (95% CI 8·23-28·92; p=0·0004), establishing the non-inferiority of cefiderocol. Cefiderocol was well tolerated. Adverse events occurred in 122 (41%) of 300 patients in the cefiderocol group and 76 (51%) of 148 patients in the imipenem-cilastatin group, with gastrointestinal disorders (ie, diarrhoea, constipation, nausea, vomiting, and abdominal pain) the most common adverse events for both treatment groups (35 [12%] patients in the cefiderocol group and 27 [18%] patients in the imipenem-cilastatin group). INTERPRETATION: Intravenous infusion of cefiderocol (2 g) three times daily was non-inferior compared with imipenem-cilastatin (1 g each) for the treatment of complicated urinary tract infection in people with multidrug-resistant Gram-negative infections. The results of this study will provide the basis for submission of a New Drug Application to the US Food and Drug Administration. Clinical trials of hospital-acquired pneumonia and carbapenem-resistant infections are ongoing. FUNDING: Shionogi & Co Ltd, Shionogi Inc.
引用
- Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018. PMID: 30509675. doi:10.1016/S1473-3099(18)30554-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。